Dupont De Nemours Inc (DD)

DuPont de Nemours, Inc. provides technology-based materials and solutions in the United States, Canada, the Asia Pacific, Latin America, Europe, the Middle East, and Africa. It operates through two segments, Healthcare & Water Technologies and Diversified Industrials. The company offers specialty components for medical devices, packaging and garments, and protective suits under the brand TYVEK; provides water filtration and separation solutions, including elements, modules, and systems serving primarily industrial wastewater and energy markets, municipal and desalination applications, and life sciences and specialty sectors. It also offers AMBERLITE ion exchange resins, FILMTEC reverse osmosis and nanofiltration elements, and INGE and ITEGRATEC ultrafiltration modules. In addition, the company offers engineered products and integrated solutions for the non-residential, residential, and repair-and-remodel construction markets, includes TYVEK house wrap, STYROFOAM insulation, and CORIAN solid surface. Further, it engages in the design and production of engineered components, systems, and process solutions used in OEM and operational applications, such as automotive, aerospace, printing, and packaging. Additionally, the company offers Vespel shapes and parts, MOLYKOTE specialty lubricants, BETAFORCE and BETASEAL structural adhesives, and Cyrel flexographic printing plates. The company was formerly known as DowDuPont Inc. and changed its name to DuPont de Nemours, Inc. in June 2019. DuPont de Nemours, Inc. was incorporated in 2015 and is headquartered in Wilmington, Delaware.

• Jahresbericht (10-K)

  Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

  Eingereicht am 2026-02-17

  Dokument ansehen

• Quartalsbericht (10-Q)

  Ein Update zur finanziellen Entwicklung der letzten drei Monate.

  Eingereicht am 2026-08-04

  Dokument ansehen

• Ad-hoc-Meldung (8-K)

  Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

  Eingereicht am 2026-09-10

  Dokument ansehen

• 4/9/2026NEGATIVE
  What's Going On With DuPont Stock Thursday?

  DuPont de Nemours, Inc. (DD) experienced a premarket decline, reflecting a broader softening in market risk appetite. While the article does not provide specific financial figures or catalysts, the downward price movement suggests investor caution. Traders will be monitoring key support levels and technical indicators for potential entry or exit points. The current market sentiment indicates a short-term bearish bias for DuPont stock, potentially influenced by macroeconomic factors or sector-specific headwinds.

• 3/9/2026NEGATIVE
  Goldman-Led Lenders Brace for Loss on Arclin Debt as Demand Cools

  Goldman Sachs-led lenders are anticipating losses on debt financing for Arclin Inc.'s acquisition of DuPont's Aramids business. Investors have shied away from the deal due to concerns over the chemical industry's volatility and demand cooling. This situation suggests potential financial distress for Arclin and could impact the value of the acquired Aramids business, indirectly affecting DuPont's sale proceeds and reputation in future divestitures. The reluctance of lenders and investors highlights significant headwinds for the sector.

• 3/4/2026NEUTRAL
  Goldman Further Sweetens Terms on Loan for DuPont Unit’s Sale

  Goldman Sachs has further sweetened terms on a downsized $1.25 billion financing package for Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. This move, despite the reduced financing amount, underscores ongoing struggles in the leveraged loan market. For investors, it signals a tight credit environment for complex M&A deals, potentially impacting valuations of similar transactions and companies' ability to fund strategic acquisitions through debt.

• 3/4/2026NEGATIVE
  Goldman-Led Buyout Loan for DuPont Unit Struggles to Find Buyers

  The sale of risky debt is becoming increasingly challenging, as evidenced by the loan offering tied to Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business, backed by Goldman Sachs. The approximately $1.1 billion transaction is struggling to find buyers due to adverse market conditions for high-yield debt. This stalemate signals a growing risk aversion among investors, which could negatively impact future financing operations and valuations of companies reliant on this type of leverage. For DuPont, this might mean a revision of divestment plans or accepting less favorable terms.

• 2/20/2026NEUTRAL
  Goldman Weighs Sweeter Terms on Loan Tied to DuPont Unit Sale

  Goldman Sachs is considering improving terms on a $1.73 billion loan tied to Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. This is a financing activity news, not directly impacting DuPont's stock value.